$0.99
2.11% yesterday
Nasdaq, Apr 07, 10:00 pm CET
ISIN
US23283X2062
Symbol
CTSO

CytoSorbents Corporation Target price 2025 - Analyst rating & recommendation

CytoSorbents Corporation Classifications & Recommendation:

Buy
50%
Hold
50%

CytoSorbents Corporation Price Target

Target Price $5.50
Price $0.99
Potential
Number of Estimates 2
2 Analysts have issued a price target CytoSorbents Corporation 2026 . The average CytoSorbents Corporation target price is $5.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 2 analysts: 1 Analysts recommend CytoSorbents Corporation to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CytoSorbents Corporation stock has an average upside potential 2026 of . Most analysts recommend the CytoSorbents Corporation stock at Buy or hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million $ 35.59 43.45
14.51% 22.07%
Net Margin -58.54% -26.50%
48.95% 54.73%

2 Analysts have issued a sales forecast CytoSorbents Corporation 2025 . The average CytoSorbents Corporation sales estimate is

$43.4m
Unlock
. This is
22.07% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$47.1m 32.23%
Unlock
, the lowest is
$39.8m 11.92%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $35.6m 14.51%
2025
$43.4m 22.07%
Unlock
2026
$53.4m 22.85%
Unlock
2027
$65.3m 22.29%
Unlock
2028
$90.6m 38.75%
Unlock
2029
$134m 48.23%
Unlock

1 Analyst has issued a net profit forecast CytoSorbents Corporation 2025 . The average CytoSorbents Corporation net profit estimate is

$-11.5m
Unlock
. This is
44.76% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-11.5m 44.76%
Unlock
, the lowest is
$-11.5m 44.76%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-20.8m 41.54%
2025
$-11.5m 44.76%
Unlock
2026
$-4.9m 57.17%
Unlock
2027
$3.3m 166.73%
Unlock
2028
$28.5m 766.57%
Unlock
2029
$66.3m 132.69%
Unlock

Net Margin

2024 -58.54% 48.95%
2025
-26.50% 54.73%
Unlock
2026
-9.25% 65.09%
Unlock
2027
5.04% 154.49%
Unlock
2028
31.48% 524.60%
Unlock
2029
49.42% 56.99%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -0.38 -0.21
41.54% 44.74%
P/E negative
EV/Sales 1.85

1 Analysts have issued a CytoSorbents Corporation forecast for earnings per share. The average CytoSorbents Corporation EPS is

$-0.21
Unlock
. This is
44.74% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.21 44.74%
Unlock
, the lowest is
$-0.21 44.74%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.38 41.54%
2025
$-0.21 44.74%
Unlock
2026
$-0.09 57.14%
Unlock
2027
$0.06 166.67%
Unlock
2028
$0.52 766.67%
Unlock
2029
$1.21 132.69%
Unlock

P/E ratio

Current -2.60 63.52%
2025
-4.72 81.54%
Unlock
2026
-11.01 133.26%
Unlock
2027
16.51 249.95%
Unlock
2028
1.90 88.49%
Unlock
2029
0.82 56.84%
Unlock

Based on analysts' sales estimates for 2025, the CytoSorbents Corporation stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.26 43.95%
2025
1.85 17.99%
Unlock
2026
1.51 18.60%
Unlock
2027
1.23 18.23%
Unlock
2028
0.89 27.93%
Unlock
2029
0.60 32.54%
Unlock

P/S ratio

Current 1.74 19.92%
2025
1.43 18.08%
Unlock
2026
1.16 18.60%
Unlock
2027
0.95 18.23%
Unlock
2028
0.68 27.93%
Unlock
2029
0.46 32.53%
Unlock

Current CytoSorbents Corporation Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Apr 03 2025
D. Boral Capital
Locked
Locked
Locked Apr 01 2025
D. Boral Capital
Locked
Locked
Locked Feb 25 2025
D. Boral Capital
Locked
Locked
Locked Jan 13 2025
D. Boral Capital
Locked
Locked
Locked Jan 03 2025
D. Boral Capital
Locked
Locked
Locked Nov 12 2024
HC Wainwright & Co.
Locked
Locked
Locked Nov 11 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 03 2025
Locked
D. Boral Capital:
Locked
Locked
Apr 01 2025
Locked
D. Boral Capital:
Locked
Locked
Feb 25 2025
Locked
D. Boral Capital:
Locked
Locked
Jan 13 2025
Locked
D. Boral Capital:
Locked
Locked
Jan 03 2025
Locked
D. Boral Capital:
Locked
Locked
Nov 12 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today